Migraine – Current Treatment – Detailed, Expanded Analysis (EU5)

According to DRG epidemiology, over 30 million people in the EU5 suffer migraines and over 10% of migraineurs suffer chronic migraine. Migraine prophylaxis is a core treatment approach for high-frequency episodic and chronic migraine patients to reduce migraine frequency, severity, and duration. Current drug treatment primarily includes a mix of off-label and approved antiepileptic drugs, beta blockers, tricyclic antidepressants, Botox (Allergan’s onabotulinumtoxinA), and—now—multiple anti-CGRP monoclonal antibodies (MAbs), the first migraine-specific preventive brands. With many agents to choose from and a heterogeneous patient population, prophylactic treatment is individualized, complex, and evolves over time. Understanding patient pathways and drivers of treatment decision-making is key for new players bringing novel brands to this large and underserved, but mostly generic, market.

QUESTIONS ANSWERED

  • What patient share do oral standards of care and injectable brands garner overall, and by line of therapy, in migraine patients treated with prophylaxis?
  • What are the drivers and constraints influencing physicians’ treatment decisions and choice of therapy for migraine prophylaxis across the EU5?
  • What role do Botox and the anti-CGRP MAbs play in the evolving treatment algorithm? Which MAb garners the most use, and why?
  • What percentage of migraine patients are treated with monotherapy versus combination therapy? How long are migraineurs treated with prophylaxis?

PRODUCT DESCRIPTION

Current Treatment: Physician Insightsprovides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Table of contents

  • Migraine - Current Treatment - Detailed, Expanded Analysis (EU5)
    • Current Treatment Physician Insights Migraine Prophylaxis EU5 November 2020